Last reviewed · How we verify
Melanoma
Approved treatments
- Keytruda · Merck & Co.
Pembrolizumab blocks PD-1 receptor, releasing immune inhibition and enhancing anti-tumor T-cell response. - Immuno-oncology (IO) · Pfizer
- Keytruda · Merck & Co.
Pembrolizumab blocks PD-1 receptor, releasing immune inhibition and enhancing anti-tumor T-cell response.
Clinical guidelines
- FDA label — 1L|adjuvant
For the treatment of adult patients with unresectable or metastatic melanoma and for the adjuvant treatment of adult and pediatric patients 12 years and older with Stage IIB, IIC, or III melanoma following complete resection. - FDA label — 1L
Adult and pediatric (12 years and older who weigh 30 kg or greater) patients with unresectable or metastatic melanoma. - FDA label — 2L
Adult and pediatric (12 years and older who weigh 30 kg or greater) patients with unresectable or metastatic melanoma following combination treatment with intravenous nivolumab and ipilimumab. - FDA label — adjuvant
Adult and pediatric (12 years and older who weigh 30 kg or greater) patients with completely resected Stage IIB, Stage IIC, Stage III, or Stage IV melanoma. - FDA label — 1L
TECENTRIQ is indicated in combination with cobimetinib and vemurafenib for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape: